Ordinary Re-Weighting | RBC Biotech Opportunities Index | Effective Date 2nd April 2024
RBC Biotech Opportunities Index:
In the ordinary re-weighting, the following composition will be implemented effective open 2nd April 2024:
| ABBVIE INC |
| ALNYLAM PHARMACEUTICALS INC |
| BIOGEN INC |
| BIOMARIN PHARMACEUTICAL INC |
| GILEAD SCIENCES INC |
| INCYTE CORP |
| INTRA-CELLULAR THERAPIES INC |
| ELI LILLY & CO |
| SAREPTA THERAPEUTICS INC |